

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

SERINC2 RABBIT PAB

Cat.#: S220899

Product Name: Anti-SERINC2 Rabbit Polyclonal Antibody

Synonyms: TDE2; TDE2L; FKSG84; PRO0899

UNIPROT ID: Q96SA4 (Gene Accession - NP_849196)

Background: SERINC2 involved in phosphatidylserine metabolic process, and positive regulation of

transferase activity.

Immunogen: Synthetic peptide of human SERINC2

Applications: ELISA, WB, IHC

Recommended Dilutions: IHC: 25-100;WB: 200-1000;ELISA: 1000-2000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG **Purification:** Antigen affinity purification **Species Reactivity:** Human, Mouse

Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol


Research Areas: Metabolism

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing




Product Description


Pioneering GTPase and Oncogene Product Development since 2010




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 220899(SERINC2 Antibody) at a dilution of 1/20(Cytoplasm).




In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 220899(Anti-SERINC2 Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using 220899(Anti-SERINC2 Antibody) at a dilution of 1/20.



In comparision with the IHC on the left, the same paraffin-embedded Human brain tissue is first treated with synthetic peptide and then with D262189(Anti-SERINC2 Antibody) at dilution 1/20.



Gel: 8%SDS-PAGE, Lysate: 40 µg;

Lane 1-6: K562 cells, NIH/3T3 cells, Jurkat cells, 293T

cells, 231 cells, hepg2 cells;

Primary antibody: 220899(SERINC2 Antibody) at

dilution 1/200;

Secondary antibody: Goat anti rabbit IgG at 1/8000

dilution;



Product Description

Pioneering GTPase and Oncogene Product Development since 2010